Characterization of novel neuroprotective ligands modulating molecular behavior of alpha synuclein in Parkinson's disease
Parkinson’s Disease (PD) is a dreadful neurodegenerative condition which consumes most of the dopaminergic neurons in the substantia nigra region of the brain causing motor and non-motor distress in affected patients. Aggregated alpha synuclein (α-syn) is the main component in cytoplasmic inclusions...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Theses and Dissertations |
| Language: | English |
| Published: |
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10356/61684 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Parkinson’s Disease (PD) is a dreadful neurodegenerative condition which consumes most of the dopaminergic neurons in the substantia nigra region of the brain causing motor and non-motor distress in affected patients. Aggregated alpha synuclein (α-syn) is the main component in cytoplasmic inclusions called Lewy bodies in surviving neurons causing widespread cellular damage. Our laboratory designed a library of novel neuroprotective ligands which have yet been characterized and is the purpose of this study. Three potential ligands were selected based on preliminary cell-based drug screening and they were shown to interact with α-syn of which a potential ligand, D38, could increase the lag-time of α-syn fibrillation in vitro. They were further tested using synucleinopathy cell-based assays in PC12 cells which exhibited their neuroprotective potential and they were also able to reduce the expression of α-syn as well. As such, these novel ligands proved to have potential neuroprotective and anti-amyloid properties for treating PD. |
|---|